This paper studies how opioid analgesic sales are empirically related to socioeconomic disparities in France, with a focus on poverty. This analysis is made possible using the OpenHealth database, which provides retail sales data for opioid analgesics available on the French market. We exploit firm-level data for each of the 94 departments in Metropolitan France between 2008 and 2017. We show that increases in the poverty rate are associated with increases in sales: a one percentage point increase in poverty is associated with approximately a 5% increase in mild opioid sales. Our analysis further shows that opioid sales are positively related to the share of middle-aged people and individuals with basic education only, while they are negatively related to population density. The granularity and longitudinal nature of these data allow us to control for a large pool of potential confounding factors. Our results suggest that additional interventions should be more intensively addressed toward the most deprived areas. We conclude that a combination of policies aimed at improving economic prospects and strictly monitoring access to opioid medications would be beneficial for reducing opioid-related harm.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884604 | PMC |
http://dx.doi.org/10.1007/s10198-022-01557-4 | DOI Listing |
Int J Drug Policy
December 2024
National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.
Background: Recent measures to curb use and harms of pharmaceutical opioids in Australia have reduced dispensings of opioid analgesics for pain, under Australia's Pharmaceutical Benefits Scheme (PBS). But information on trends in private (self-funded) dispensings and public (government-funded) hospital opioids use is not readily available. Our study describes eight-year population-level trends in Australia's prescribed opioid analgesic use, estimating PBS dispensing claims, private dispensings and hospital use.
View Article and Find Full Text PDFHarm Reduct J
November 2024
Northeast & Caribbean Prevention Technology Center, Center for Prevention Science, School of Social Work, Rutgers, The State University of New Jersey, 390 George Street, 5th Floor, New Brunswick, NJ, 08901, USA.
J Am Pharm Assoc (2003)
November 2024
UNC Eshelman School of Pharmacy, 201 Pharmacy Lane, CB 7355, Chapel Hill, NC, 27599-7355, USA.
Background: There's limited information available about the range of harm reduction (HR) services provided by rural pharmacies.
Objective: This study's objectives are to describe the types of HR services offered by rural pharmacies and examine pharmacists' attitudes and willingness to offer those services.
Methods: A cross-sectional online survey was sent to pharmacists who are members of a practice-based research network for rural community pharmacies.
Br J Clin Pharmacol
November 2024
REQUIMTE/LAQV, Escola Superior de Saúde, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, Porto, Portugal.
Aims: This study evaluated the 10-year consumption and economic patterns of classical analgesics, adjuvants and opioids in Portugal (2012-2022), and conducted a comparative analysis between Portugal, Spain and Denmark to explore the consumption patterns among these countries for 2022.
Methods: Data on sales and national health service (NHS) costs were obtained from the Portuguese National Authority of Medicines and Health Products. Sales data were converted to defined daily dose (DDD) per 1000 inhabitants per day according to the Anatomical Therapeutic Chemical (ATC) classification/DDD methodology, while comparisons between Spain and Denmark were evaluated with the chi-square test, when appropriate.
JAMA Health Forum
November 2024
Division of Research, Kaiser Permanente Northern California, Pleasanton.
Importance: It is unknown whether state recreational cannabis legalization (RCL) is related to increased rates of prenatal cannabis use or whether RCL-related changes vary with cannabis screening methods or the local policy environment.
Objective: To test whether RCL in California was associated with changes in prenatal cannabis use rates, whether changes were evident in both self-report and urine toxicology testing, and whether rates varied by local policies banning vs allowing adult-use retailers post-RCL.
Design, Setting, And Participants: This population-based time-series study used data from pregnancies in Kaiser Permanente Northern California universally screened for cannabis use during early pregnancy by self-report and toxicology testing from January 1, 2012, to December 31, 2019.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!